Roxane Agrees To Hold Off On Generic Asacol

Law360, New York (March 12, 2010, 1:52 PM EST) -- Roxane Laboratories Inc. has agreed to delay its launch of a generic version of inflammatory bowel drug Asacol until as late as November as part of a discovery agreement in a patent infringement suit brought by Procter & Gamble Pharmaceuticals Inc. and Medeva Pharma Suisse AG.

Roxane filed a stipulation Thursday in the U.S. District Court for the District of New Jersey agreeing not to sell the drug before Nov. 1 or “the date of favorable judgment, whichever is earlier,” even though the U.S. Food and...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.